切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2022, Vol. 10 ›› Issue (01) : 27 -31. doi: 10.3877/cma.j.issn.2095-5782.2022.01.005

肿瘤介入

血必净注射液辅助治疗原发性肝癌介入术后综合征的临床研究
李辉1,(), 李海霞2, 王秀香1   
  1. 1. 061014 河北沧州,沧州市传染病医院CT科
    2. 061014 河北沧州,沧州市传染病医院放射科
  • 收稿日期:2021-02-01 出版日期:2022-02-25
  • 通信作者: 李辉

Efficacy of Xuebijing injection in the treatment of post-interventional Syndrome of primary liver cancer and its effects on liver function and serum CRP, TNF-AND VEGF levels

Hui Li1,(), Haixia Li2, Xiuxiang Wang1   

  1. 1. CT Department, Cangzhou Infectious Disease Hospital, Hebei Cangzhou 061014, China
    2. Radiology Department, Cangzhou Infectious Disease Hospital, Hebei Cangzhou 061014, China
  • Received:2021-02-01 Published:2022-02-25
  • Corresponding author: Hui Li
引用本文:

李辉, 李海霞, 王秀香. 血必净注射液辅助治疗原发性肝癌介入术后综合征的临床研究[J/OL]. 中华介入放射学电子杂志, 2022, 10(01): 27-31.

Hui Li, Haixia Li, Xiuxiang Wang. Efficacy of Xuebijing injection in the treatment of post-interventional Syndrome of primary liver cancer and its effects on liver function and serum CRP, TNF-AND VEGF levels[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(01): 27-31.

目的

探讨血必净注射液治疗原发性肝癌(PHC)介入术后综合征的疗效及对肝功能和血清C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和血管内皮生长因子(VEGF)水平的影响。

方法

将我院收治的102例PHC介入术后综合征患者随机分成两组,每组51例。两组均给予常规治疗,观察组联合血必净注射液治疗,比较两组的疗效和安全性。比较两组治疗前后中医证候总积分、肝功能指标[谷草转氨酶(AST)、谷丙转氨酶(ALT)、总胆红素(TBIL)]、血清CRP、TNF-α和VEGF水平的变化情况。

结果

观察组总有效率为80.39%,与对照组的56.86%相比显著上升(P < 0.05)。两组术后3、7 d中医证候总积分均显著下降(P < 0.05);且以观察组降低更显著(P < 0.05)。观察组肝区疼痛、发热、恶心呕吐、腹泻的持续时间均显著短于对照组(P < 0.05)。两组术后3 d时血清ALT、AST、TBIL、CRP、TNF-α水平均较本组术前显著升高(P < 0.05),术后7 d时则均较本组术后3 d时显著降低(P < 0.05);且观察组术后3、7 d时血清ALT、AST、TBIL、CRP、TNF-α水平均显著低于对照组同时点(P < 0.05)。两组术后血清VEGF水平均显著升高(P < 0.05),但术后7 d相比观察组显著更低(P < 0.05)。所有受试者均无明显不良反应发生。

结论

血必净注射液辅助治疗PHC介入术后综合征能有效抑制血清炎性因子与VEGF表达,减轻肝损伤,疗效确切。

Objective

To investigate the efficacy of Xuebijing injection on hepatic function and serum c-reactive protein (CRP) , tumor necrosis Factor-alpha (TNF-α) and Vascular endothelial growth factor in patients with primary hepatic Carcinoma (PHC) after interventional therapy.

Methods

A total of 102 patients with PHC Post-intervention Syndrome were randomly divided into two groups, 51 cases in each group.Two groups were given conventional treatment, observation group combined with Xuebijing injection treatment. The efficacy and safety of the two groups were compared. The changes of TCM syndrome total score, liver function index [aspartate transaminase, alanine transaminase, total Bilirubin (TBIL)], the levels of serum CRP, TNF-α and VEGF were compared between the two groups before and after treatment.

Results

The total effective rate of the observation group was 80.39%, which was significantly higher than that of the control group (56.86%)(P < 0.05). The total score of TCM Syndrome in both groups decreased significantly (P < 0.05) on the 3rd and 7th days after operation, and the decrease was more significant in the observation group (P < 0.05). The duration of pain, fever, nausea, vomiting and diarrhea in the observation group was significantly shorter than that in the control group (P < 0.05). The levels of serum ALT, AST, TBIL, CRP and TNF-α in the two groups were significantly increased 3 d after the operation compared with those before operation (P < 0.05), and significantly decreased 7 d after the operation compared with those 3 d after the operation (P < 0.05) The serum levels of ALT, AST, TBIL, CRP and TNF-α in the observation group were significantly lower than those in the control group at the same time point (P < 0.05). The levels of serum VEGF in the two groups were increased significantly after the operation (P < 0.05). However, the serum VEGF level in observation group was significantly lower than that in control group 7 days after operation (P < 0.05). There was no obvious adverse reaction in all subjects.

Conclusions

Xuebijing injection can effectively inhibit the expression of serum inflammatory factors and VEGF and alleviate liver injury in patients with PHC post-interventional syndrome.

表1 两组一般资料比较
表2 两组临床疗效比较[n(%)]
表3 两组术前及术后3、7 d时中医证候总积分比较(±s,分)
表4 两组临床症状持续时间比较(±s,d)
表5 两组术前及术后3、7 d时血清肝功能指标水平比较(±s
表6 两组术前及术后3、7 d时血清CRP、TNF-α和VEGF水平比较(±s
[1]
万赤丹, 王国斌. 原发性肝癌治疗进展[J]. 腹部外科, 2019, 32(1): 1-6, 22.
[2]
Koya S, Kawaguchi T, Hashida R, et al. Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization[J]. J Gastroenterol Hepatol, 2019, 34(3): 580-588.
[3]
Shiozawa S, Usui T, Kuhara K, et al. Significance of transcatheter arterial chemoembolization for BCLC stage B hepatocellular carcinoma with mal-nutrition[J]. Gan To Kagaku Ryoho, 2018, 45(2): 350-352.
[4]
余静芳, 周晓玲, 陈峭, 等. 麻黄升麻汤治疗乙肝相关性原发性肝癌TACE术后栓塞综合征的疗效观察[J]. 辽宁中医药大学学报, 2018, 20(3): 136-139.
[5]
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292.
[6]
中华人民共和国卫生部政司. 中国常见恶性肿瘤诊治规范第二分册原发性肝癌[M]. 北京: 北京医科大学中国协和医科大学联合出版社, 1991: 2-54.
[7]
国家中医药管理局. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 156.
[8]
Kuwaki K, Nouso K, Miyashita M, et al. The efficacy and safety of steroids for preventing postembolization syndrome after transcatheter arterial chemoembolization of hepatocellular carcinoma [J]. Acta medica Okayama, 2019, 73(4): 333-339.
[9]
何伟, 赵许亚, 李俊祥, 等. 肝癌介入治疗对原发性肝癌中晚期患者的效果及肝功能的影响[J]. 实用临床医药杂志, 2017, 21(3): 71-74.
[10]
龚辉, 唐建清, 陈州华, 等. 柴芍六君子汤防治肝癌TACE术后栓塞综合征的临床研究[J].中医药导报, 2018, 24(22): 36-38.
[11]
闫春江, 黎永琳, 李燕, 等. 血必净注射液对脓毒症患者血清miR-223及高迁移率族蛋白B1表达的影响[J]. 疑难病杂志, 2019, 18(3): 243-246.
[12]
李娟, 林志芳. 异甘草酸镁对原发性肝癌肝动脉化疗栓塞术后炎症反应的影响及肝损伤的保护作用[J]. 中国现代普通外科进展, 2020, 23(3): 228-230.
[13]
马世堂, 俞浩, 张孝林, 等. 血必净组方药效物质基础与脓毒症多靶点作用效应研究[J]. 中国中西医结合杂志, 2015, 35(11): 1351-1355.
[14]
孙梦杰, 屠亚茹, 欧阳慧子, 等. 血必净注射液及其药代标示物对脓毒症大鼠炎性因子TNF-α, IL-1, IL-6, IL-8和IL-10表达的影响[J]. 天津中医药大学学报, 2018, 37(1): 13-15.
[15]
Liu X, Hu Z, Zhou B, et al. Chinese herbal preparation Xuebijing potently inhibits inflammasome activation in hepatocytes and ameliorates mouse liver ischemia-reperfusion injury[J]. PLoS One, 2015, 10(7): e131436.
[16]
刘俊, 武金才, 郑进方, 等.中晚期肝癌介入治疗后应用血必净的临床疗效观察[J]. 海南医学, 2018, 29(3): 413-415.
[17]
常旭, 张林, 孙鹏, 等. 右肾包膜动脉化疗栓塞在原发性肝癌介入治疗中的安全性及有效性研究[J]. 中华介入放射学电子杂志, 2020, 8(2): 135-140.
[1] 黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[2] 马立伟, 贾志强, 陈午盛, 邵明亮, 刘琼, 段玉松. CalliSpheres载药微球联合碘化油治疗肝癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 369-372.
[3] 刘炯, 彭乐, 马伟, 江斌. 鞘外解剖肝蒂技术治疗肝内胆管细胞癌的疗效评估[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 373-376.
[4] 王东阳, 林琳, 娄熙彬. SII对局部进展期胃癌nCRT+腹腔镜胃癌根治术后并发症及预后的影响研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(03): 315-318.
[5] 唐亦骁, 陈峻, 连正星, 胡海涛, 鲁迪, 徐骁, 卫强. 白果内酯对小鼠肝缺血再灌注损伤保护作用研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 278-282.
[6] 朱佳琳, 方向, 贵诗雨, 黄丹, 周小雨, 郭文恺. 大鼠切口疝腹膜前间隙补片修补术后血清中VEGF 和Ang-1 的表达情况[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 703-707.
[7] 李智, 冯芸. NF-κB 与MAPK 信号通路及其潜在治疗靶点在急性呼吸窘迫综合征中的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 840-843.
[8] 张敏龙, 杨翠平, 王博, 崔云杰, 金发光. MiR-200b-3p 通过抑制HIF-1α 表达减轻海水吸入诱导的肺水肿作用及机制[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 696-700.
[9] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[10] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[11] 傅斌生, 冯啸, 杨卿, 曾凯宁, 姚嘉, 唐晖, 刘剑戎, 魏绪霞, 易慧敏, 易述红, 陈规划, 杨扬. 脂肪变性供肝在成人劈离式肝移植中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 789-794.
[12] 伍细蓉, 徐立文, 陈亚琼. 基于LPR和FARI构建肝衰竭患者生存预后模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 675-681.
[13] 钟造茂, 罗文超, 蔡满航, 陈显育, 钟跃思. 肝癌肝切除术后肝衰竭的危险因素分析及列线图模型构建[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 289-295.
[14] 刘建勇, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植治疗Ⅳ级肝昏迷疗效及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 344-349.
[15] 陈雪飞, 卜雄建, 张春良. 神经内镜下经鼻蝶窦扩大鞍底入路颅咽管瘤切除术的疗效分析[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(03): 160-165.
阅读次数
全文


摘要